Table 1. Demographic characteristics, prior seasonal influenza vaccine, and study site, by study group.
| Group 1A | Group 1B | Group 1C | Group 2A | Group 2B | Group 2C | Group 3 | Group 4 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VARIABLES | 15μg H7N9+ IB160 | 7.5μg H7N9 + IB160 | 3.75μg H7N9 + IB160 | 15μg H7N9 + SE | 7.5μg H7N9 + SE | 3.75μg H7N9 + SE | 15μg H7N9, without adjuvant | Placebo | TOTAL | |||||||||
| (n = 53) | (n = 53) | (n = 54) | (n = 53) | (n = 55) | (n = 54) | (n = 54) | (n = 54) | (n = 430) | ||||||||||
| Age (years) | P50 | (P25-P75) | P50 | (P25-P75) | P50 | (P25-P75) | P50 | (P25-P75) | P50 | (P25-P75) | P50 | (P25-P75) | P50 | (P25-P75) | P50 | (P25-P75) | P50 | (P25-P75) |
| 38 | (30.3–46.6) | 35 | (27.9–41.5) | 35 | (29.1–43.2) | 39 | (28.5–47.2) | 37 | (29.0–46.6) | 36 | (25.3–43.9) | 34 | (24.6–42.6) | 35 | (26.2–42.1) | 35.4 | (27.5–44.0) | |
| Sex | n | (%) | n | (%) | n | (%) | n | (%) | n | (%) | n | (%) | n | (%) | n | (%) | n | (%) |
| Female | 37 | (69.8) | 44 | (83.0) | 37 | (68.5) | 37 | (69.8) | 35 | (63.6) | 35 | (64.8) | 35 | (64.8) | 40 | (74.1) | 300 | (69.8) |
| Male | 16 | (30.2) | 9 | (17.0) | 17 | (31.5) | 16 | (30.2) | 20 | (36.4) | 19 | (35.2) | 19 | (35.2) | 14 | (25.9) | 130 | (30.2) |
| Ethnicity | n | (%) | n | (%) | n | (%) | n | (%) | n | (%) | n | (%) | n | (%) | n | (%) | n | (%) |
| Asian | 0 | (0.0) | 3 | (5.7) | 1 | (1.9) | 3 | (5.7) | 1 | (1.8) | 0 | (0.0) | 1 | (1.9) | 2 | (3.7) | 11 | (2.6) |
| Black | 6 | (11.3) | 9 | (17.0) | 8 | (14.8) | 4 | (7.6) | 8 | (14.6) | 7 | (13.0) | 13 | (24.1) | 9 | (16.7) | 64 | (14.9) |
| Brazilian Indigenous | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 1 | (1.9) | 1 | (0.2) |
| Multiracial | 12 | (22.6) | 11 | (20.8) | 15 | (27.8) | 11 | (20.8) | 10 | (18.2) | 10 | (18.5) | 11 | (20.4) | 10 | (18.5) | 90 | (20.9) |
| White | 35 | (66.0) | 30 | (56.6) | 30 | (55.6) | 35 | (66.0) | 36 | (65.5) | 37 | (68.5) | 29 | (53.7) | 32 | (59.3) | 264 | (61.4) |
| Prior seasonal influenza vaccine | n | (%) | n | (%) | n | (%) | n | (%) | n | (%) | n | (%) | n | (%) | n | (%) | n | (%) |
| None | 12 | (22.6) | 11 | (20.8) | 15 | (27.8) | 13 | (24.5) | 11 | (20.0) | 16 | (29.6) | 20 | (37.0) | 19 | (35.2) | 117 | (27.2) |
| 2017 only | 3 | (5.7) | 4 | (7.6) | 2 | (3.7) | 3 | (5.7) | 5 | (9.1) | 2 | (3.7) | 3 | (5.6) | 1 | (1.9) | 23 | (5.4) |
| 2018 only | 3 | (5.7) | 2 | (3.8) | 4 | (7.4) | 4 | (7.6) | 5 | (9.1) | 6 | (11.1) | 2 | (3.7) | 4 | (7.4) | 30 | (7.0) |
| 2017 and 2018 | 34 | (64.2) | 34 | (64.2) | 33 | (61.1) | 30 | (56.6) | 32 | (58.2) | 29 | (53.7) | 25 | (46.3) | 28 | (51.9) | 245 | (57.0) |
| Unkown* | 1 | (1.9) | 2 | (3.8) | 0 | (0.0) | 3 | (5.7) | 2 | (3.6) | 1 | (1.9) | 4 | (7.4) | 2 | (3.7) | 15 | (3.5) |
| Study site | n | (%) | n | (%) | n | (%) | n | (%) | n | (%) | n | (%) | n | (%) | n | (%) | n | (%) |
| HCFMUSP | 15 | (28.3) | 15 | (28.3) | 15 | (27.8) | 15 | (28.3) | 15 | (27.3) | 15 | (27.8) | 15 | (27.8) | 15 | (27.8) | 120 | (27.9) |
| ICr-HCFMUSP | 15 | (28.3) | 15 | (28.3) | 15 | (27.8) | 14 | (26.4) | 15 | (27.3) | 15 | (27.8) | 15 | (27.8) | 15 | (27.8) | 119 | (27.7) |
| HCFMRP- USP | 23 | (43.4) | 23 | (43.4) | 24 | (44.4) | 24 | (45.3) | 25 | (45.5) | 24 | (44.4) | 24 | (44.4) | 24 | (44.4) | 191 | (44.4) |
adj: adjuvant; P50: median; P25: first quartile; P75: third quartile
* any Unknown answer